Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
AIM ImmunoTech Inc (AIM)
NYSE MKT:AIM
Holding AIM?
Track your performance easily
AIM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.16 - $0.62
Previous Close$0.2
Volume512.28K
Average Volume (3M)403.88K
Market Cap
$12.27M
Enterprise Value$7.86M
Total Cash (Recent Filing)$7.20M
Total Debt (Recent Filing)$3.40M
Price to Earnings (P/E)―
Beta1.51
Next Earnings
Apr 07, 2025EPS Estimate
-$0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.47
Shares Outstanding63,706,446
10 Day Avg. Volume1,087,440
30 Day Avg. Volume403,882
Standard Deviation0.26
R-Squared0.00543
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)4.00
Price to Sales (P/S)61.36
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue45.42
Enterprise Value/Gross Profit49.11
Enterprise Value/Ebitda-0.44
Forecast
1Y Price Target
$3.00Price Target Upside1325.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
AIM ImmunoTech News
PremiumCompany Announcements
Aim Immunotech Reports Third Quarter EarningsOwnership Overview
3.50% Insiders
3.79% Mutual Funds
7.09% Other Institutional Investors
82.58% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
AIM FAQ
What was AIM ImmunoTech Inc’s price range in the past 12 months?
AIM ImmunoTech Inc lowest stock price was $0.16 and its highest was $0.62 in the past 12 months.
What is AIM ImmunoTech Inc’s market cap?
Currently, no data Available
When is AIM ImmunoTech Inc’s upcoming earnings report date?
AIM ImmunoTech Inc’s upcoming earnings report date is Apr 07, 2025 which is in 137 days.
How were AIM ImmunoTech Inc’s earnings last quarter?
AIM ImmunoTech Inc released its earnings results on Nov 15, 2024. The company reported -$0.06 earnings per share for the quarter, the consensus estimate of -$0.06 by $0.
Is AIM ImmunoTech Inc overvalued?
According to Wall Street analysts AIM ImmunoTech Inc’s price is currently Undervalued.
Does AIM ImmunoTech Inc pay dividends?
AIM ImmunoTech Inc does not currently pay dividends.
What is AIM ImmunoTech Inc’s EPS estimate?
AIM ImmunoTech Inc’s EPS estimate is -$0.1.
How many shares outstanding does AIM ImmunoTech Inc have?
AIM ImmunoTech Inc has 63,706,448 shares outstanding.
What happened to AIM ImmunoTech Inc’s price movement after its last earnings report?
AIM ImmunoTech Inc reported an EPS of -$0.06 in its last earnings report, expectations of -$0.06. Following the earnings report the stock price went down -12%.
Which hedge fund is a major shareholder of AIM ImmunoTech Inc?
Currently, no hedge funds are holding shares in AIM
---
AIM ImmunoTech Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.00 (1325.18% Upside)
$3.00 (1325.18% Upside)
Insider Transactions
Bought Shares
Worth $50.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 1.2%
Last 30 Days ▼ 1.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-51.69%
12-Months-Change
Fundamentals
Return on Equity
-187.58%
Trailing 12-Months
Asset Growth
-51.23%
Trailing 12-Months
Company Description
AIM ImmunoTech Inc
AIM ImmunoTech, Inc. operates as a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Orlando, FL.
---
AIM Earnings Call
Q3 2024
0:00 / 0:00
---
AIM Stock 12 Month Forecast
Average Price Target
$3.00
▲(1325.18% Upside)
Technical Analysis
Best Analysts Covering AIM
1 Year
1 Year Success Rate
1/10 ratings generated profit
1 Year Average Return
-31.16%
reiterated a buy rating last month
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 10.00% of your transactions generating a profit, with an average return of -31.16% per trade.
---